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Abstract
Objective: Myosin binding protein C (MYBPC3) plays a role in ventricular relaxation. The aim of the study was to investigate
the association between cardiac myosin binding protein C (MYBPC3) gene polymorphisms and diastolic heart failure (DHF) in
a human case-control study.
Methods: A total of 352 participants of 1752 consecutive patients from the National Taiwan University Hospital and its
affiliated hospital were enrolled. 176 patients diagnosed with DHF confirmed by echocardiography were recruited. Controls
were matched 1-to-1 by age, sex, hypertension, diabetes, renal function and medication use. We genotyped 12 single
nucleotide polymorphisms (SNPs) according to HapMap Han Chinese Beijing databank across a 40 kb genetic region
containing the MYBPC3 gene and the neighboring DNA sequences to capture 100% of haplotype variance in all SNPs with
minor allele frequencies §5%. We also analyzed associations of these tagging SNPs and haplotypes with DHF and linkage
disequilibrium (LD) structure of the MYBPC3 gene.
Results: In a single locus analysis, SNP rs2290149 was associated with DHF (allele-specific p=0.004; permuted p=0.031). The
SNP with a minor allele frequency of 9.4%, had an odds ratio 2.14 (95% CI 1.25–3.66; p=0.004) for the additive model and
2.06 for the autosomal dominant model (GG+GA : AA, 95% CI 1.17–3.63; p=0.013), corresponding to a population
attributable risk fraction of 12.02%. The haplotypes in a LD block of rs2290149 (C-C-G-C) was also significantly associated
with DHF (odds ratio 2.10 (1.53–2.89); permuted p=0.029).
Conclusions: We identified a SNP (rs2290149) among the tagging SNP set that was significantly associated with early DHF in
a Chinese population.
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Introduction
Heart failure is a common hemodynamic and neurohormonal
syndrome, the prevalence of which is increasing as the population
ages [1]. Diastolic heart failure (DHF) and systolic heart failure
(SHF) are the two most commonly encountered forms of heart
failure in clinical practice. Clinically, overt DHF and SHF appear
to be two separate syndromes that have distinctive morphologic
and functional change characteristics; however the signs, symp-
toms, and prognoses of both syndromes are very similar [2].
Structurally, patients with SHF have eccentric left ventricular (LV)
hypertrophy, whereas patients with DHF have concentric LV
hypertrophy [3]. From a molecular perspective, the cytoskeletal
protein titin, matrix metalloproteinase degradation, and impaired
calcium homeostasis have been linked with DHF [4–7]. We have
previously reported on genetic factors that may contribute to the
development and prognosis of DHF [8,9]. However, the precise
genetic etiology of DHF remains poorly understood.
The Myosin binding protein C (MYBPC3) gene encodes myosin
binding protein C, a key constituent of the thick filaments localized
to doublets in the C-zone of the A-band of the sarcomere. By
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maintaining the structural integrity of the sarcomere and regulates
cardiac contractility in response to adrenergic stimulation [10].
Findings from a recent study suggest that MYBPC3 can inhibit the
myosin-actin interaction, allowing complete relaxation during
diastole, and that MYBPC3 ablation causes defective diastolic
relaxation [11]. MYBPC3 gene mutations have also been
demonstrated to be associated with a risk of delayed, mild
hypertrophic heart failure [12] and hypertrophic cardiomyopathy
(HCM) [13]. However, findings from a mouse gene knock-out
study have revealed that MYBPC3 gene mutation was associated
with concentric LV hypertrophy and mildly impaired contractile
function, a characteristic feature of DHF [14] Given these findings
we hypothesized that MYBPC3 gene variations may affect an
individual’s susceptibility to develop DHF.
Recently a 25-bp deletion polymorphism in intron 32 of the
MYBPC3 gene was identified in south Asians and found to be
associated with an increased risk of cardiomyopathy [12]. In the
present study, we investigated if this common deletion variant was
also present in a Han Chinese population and if the variant was
associated with an increased risk of DHF. We also screened for
other common MYBPC3 variants in the same Han Chinese
population. Single nucleotide polymorphisms (SNPs) tagging
common variations across the MYBPC3 gene were selected
according the HapMap Han Chinese Beijing databank (CHB)
group (http://www.hapmap.org/). Associations between DHF
and linkage disequilibrium (LD) structure among the MYBPC3
gene tagging SNP set were analyzed. We found that there was no
deletion variant in our population. However, we found for the first
time that a SNP among the tagging SNP set was significantly
associated with an increased risk of early DHF.
Methods
Ethics Statement
We certify that all the applicable institutional and governmental
regulations concerning the ethical use of human volunteers/
animals were followed during this research. Written informed
consent was obtained from every participating subject, and the
study was approved by the institutional review board of the
National Taiwan University Hospital (approval ID: 20070313R).
Screening for the MYBPC3 gene deletion
A 25 bp deletion in intron 32 of MYBPC3 gene was previously
reported to be associated with cardiomyopathies, including
hypertrophic and dilated cardiomyopathies. We screened DNA
samples from 400 individuals in a population of Taiwanese
patients with cardiomyopathies. The methods used have been
described in detail previously [12].
Case-control study participants and study design
A total of 1752 consecutive patients from the cardiovascular
ward or clinic of the National Taiwan University Hospital and an
affiliated hospital were recruited from July 2005 through April
2008. All patients underwent echocardiography. Diastolic heart
failure was defined as previously described and according to recent
guidelines [8,15]. Briefly, the definitions used included: exertional
dyspnea (New York Heart Association function class II–III); heart
failure as defined by the Framingham criteria and normal systolic
function (ejection fraction $50%); and echocardiographic evi-
dence of LV diastolic dysfunction ie, a mitral inflow E/A ratio ,1,
deceleration time .220 cm/s, and decreased peak annular early
diastolic velocity of the lateral mitral annulus ,8 cm/s upon tissue
Doppler imaging. Patients who had renal failure, significant
hepatic disease, secondary hypertension, a history of myocardial
infarction, significant coronary artery disease (CAD; coronary
artery stenosis $70%), pericardial disease, significant valvular
heart disease ($moderate), chronic obstructive pulmonary disease,
or chronic atrial fibrillation were excluded. The control population
comprised risk-factor matched control patients. For every case
patient, a matched control with no symptoms of heart failure and
no objective evidence of diastolic dysfunction (a mitral inflow E/A
ratio between 1,2, deceleration time ,220 cm/s, and decreased
peak annular early diastolic velocity of the lateral mitral annulus
.8 cm/s upon tissue Doppler imaging) was selected from the
same ward or clinic. Cases and controls were individually matched
by sex, age (difference#5 years), blood pressure, diabetes status,
renal function, and medication use. A total of 176 patients with
DHF (96 men and 80 women) and 176 matched controls were
selected for study.
Echocardiography
Left atrial diameter, LV end diastolic and systolic diameter,
interventricular septum thickness, LV posterior wall thickness,
mitral inflow early rapid filling wave (E), peak velocity of the late
filling wave due to atrial contraction (A), the E/A ratio, E wave
deceleration time, and mitral annular early diastolic velocity were
measured according to American Society of Echocardiography
guidelines using a Sonos 7500 echocardiography probe (Philips,
Andover, MA) attached to a 1 to 3 MHz transducer. The LV
ejection fraction was calculated as previously described [12]. The
LV mass index (LVMI) was calculated from the LV end diastolic
and systolic diameter, interventricular septum thickness, and LV
posterior wall thickness according to the method of Devereux et
al [14]. Doppler and color Doppler studies were performed to
detect valvular heart disease. Significant valvular heart disease
was defined as at least moderate aortic or mitral stenosis/
regurgitation.
Selection of SNPs and genotyping
Using the HapMap CHB databank (public data release 21 a/
phase II, Jan. 2007), 103 SNPs were identified in a 40 kb gene
region containing the MYBPC3 gene and parts of an upstream
(SPI1)a n dd o w n s t r e a mg e n e( MADD). To identify common
h a p l o t y p et a g g i n gS N P s ,e l i g i b l eS N P sw e r ee n t e r e di n t ot h e
Tagger program in Haploview version 3.32 [16]. (http://www.
broad.mit.edu/mpg/haploview/). The minor allele frequency
threshold was 5% (r
2=0.8. Twelve tag SNPs (rs10838692,
rs11039179, rs2290149, rs7124958, rs753992, rs2305280,
rs10769253, rs2856650, rs2697920, rs1057233, rs3824869, and
rs3740689) were selected, capturing 100% of haplotype variance
for all SNPs on the MYBPC3 gene with minor allele frequencies
$5%. All SNP markers were genotyped by matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-
TOF MS) [15,17]. A DNA fragment (100–300 bp) encompassing
the SNP site was amplified using a polymerase chain reaction
GeneAmp 9700 thermocycler (Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. After polymer-
ase chain reaction amplification and neutralization of the
deoxynucleotide triphosphates (dNTP), primer extension was
performed by adding the probe, Thermo Sequenase (Amer-
sham Pharmacia, Piscataway, NJ), and an appropriate
dideoxynucleotide triphosphate/dNTP mixture. Extension
products were differentiated by MALDI-TOF. We then
compared the reference allele frequency and MAF of our
population with other populations announced in the HapMap
databank (Tables S1).
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Baseline characteristics and echocardiographic findings were
compared between groups using Student’s unpaired t-test
(continuous data) or chi-square test (categorical data). We
calculated the power of the single locus analyses using the Genetic
Power Calculator (http://pngu.mgh.harvard.edu/,purcell/gpc/)
[18]. To detect an odds ratio of 1.6 (autosomal dominance), with a
two-sided alpha error of 0.05, the calculated power was 0.57 to
0.90, with the percentage of having at least one variant allele
(dominant model) ranging from 0.1 to 0.5. The association
between each SNP and haplotype and DHF was estimated using
Haploview software. A Hardy-Weinberg equilibrium (HWE) test
was performed for each sequence variant of the control group
before marker-trait association analysis [16]. Nominal two-sided P
values were corrected for multiple tests by 10,000 times
permutation. For haplotype construction, genotype data from
the case and control groups were used to estimate intermarker
linkage disequilibrium (LD) by measuring pairwise D9 and r
2 and
defining LD blocks. We used the confidence interval (CI) method
component of the Haploview software to define an LD block with
an extended spine if D9 was .0.8 [17]. The population
attributable risk (PAF) was estimated data from the control group
data as follows: 12{1/[p2O R homo+2p(12p)ORhetero+(12p)
2]},
where p is the risk-allele frequency, ORhomo is the odds ratio (OR)
for homozygotes, and ORhetero is the OR for heterozygotes.
Results
Baseline characteristics
The baseline characteristics of the study participants are shown
in Table 1. All baseline characteristics were similar between the
case and control groups. The echocardiographic parameters of the
study participants are shown in Table 2. Although IVS and LVPW
thicknesses were higher in the DHF group, there was no between
group difference in LVMI. This suggests that the degree of LV
hypertrophy, which can affect diastolic function, was similar
between the groups. Case group participants had a significantly
lower mitral inflow E/A ratio, a longer mitral inflow deceleration
time, and a shorter mitral annular early diastolic velocity than
control group participants. The participants of our current study
are similar to the recent prospective, multi-centered, randomized,
open-label study in Chinese DHF patients [19]. Most participants
in the DHF group were classified as having at least grade I
diastolic dysfunction (Table 2) [20].
MYBPC3 gene deletion
We screened 400 healthy Taiwanese individuals for the 25 bp
MYBPC3 gene deletion polymorphism. None of the screened
individuals had the previously described [12] 25 bp gene deletion
in intron 32 of the MYBPC3 gene.
Characteristics of the SNPs and LD structures of MYBPC3
gene
On average, 99.15% of attempted genotypes were successful
(success rates ranged from 97.8% to 99.9% for each SNP). The
concordance rate of genotyping duplication was 99.37%. The
MYBPC3 gene, located on chromosome 11, is 22 kb in length with
34 exons and introns. The adjacent genes are SPI1 (upstream) and
MADD (downstream). A graphic representation of the SNPs in
relation to the exon-intron structure (according to the National
Center for Biotechnology Information) is shown in Figure 1. Most
SNPs were located in introns, except for SNP rs1057233, which
was located in the 59 upstream promoter region. The genomic
Table 1. Baseline characteristics of patients and controls.
Characteristic DHF (n=176) Matched Controls (n=176) P
Age (years) 63.7610.9 62.3611.1 0.23
Sex (male/female) 96/80 96/80 1.00
BMI (kg/m
2)2 5 . 6 63.2 24.262.9 ,0.001
Diabetes mellitus (%) 13 10 0.13
Hypertension (%) 59 58 0.91
Creatinine (mg/dL) 0.9960.28 0.9860.23 0.8
Anti-hypertension therapy
ACEI+ARB 26 20 0.31
b-blocker 34 30 0.49
Calcium channel blocker 49 41 0.11
DHF, diastolic heart failure; BMI, body mass index; BP, blood pressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type I receptor blocker.
doi:10.1371/journal.pone.0035242.t001
Table 2. Echocardiographic data.
Variable DHF (n=176) Control (n=176) P
LA diameter (mm) 35.065.1 34.265.8 0.21
LVEF (%) 70.567.9 71.368.0 0.35
IVS (mm) 11.661.8 10.961.7 ,0.001
LVPW (mm) 11.161.9 10.561.6 0.003
LVEDD (mm) 45.165.1 45.465.4 0.56
LVESD (mm) 26.865.2 26.865.2 0.93
LVMI (g/m
2) 126.67637.23 116.59636.84 0.15
E (cm) 62.9615.9 84.3619.3 ,0.001
A (cm) 85.9615.8 67.9618.5 ,0.001
DT (cm/s) 242.8641.9 162.8640.1 ,0.001
Mitral Ea (cm/s) 7.361.9 10.962.05 ,0.001
DHF, diastolic heart failure; LA, left atrium; LVEF, left ventricular ejection
fraction; IVS, interventricular septum; LVPW, left ventricular posterior wall;
LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end
systolic dimension; LVMI, left ventricular mass index; E, mitral valve ejection
flow; A, mitral valve atrium flow; DT, deceleration time; Mitral Ea, peak mitral
annular early diastolic velocity.
doi:10.1371/journal.pone.0035242.t002
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allele frequencies of the 12 genotyped SNPs are summarized in
Table 3.
MYBPC3 gene polymorphisms and DHF association
analysis
To determine the extent of LD in the MYBPC3 gene, genotype
data from both the case and control groups were used to estimate
intermarker LD. Standardized pairwise LD coefficients D9 and r
2
between markers were estimated and two LD blocks were
identified across the gene (Figure 1). We found that rs2290149
was significantly associated with DHF (nominal P=0.004)
(Table 3). The association remained significant after correcting
for multiple testing (permuted P=0.031) (Table 3). The SNP
with a minor allele frequency of 9.4%, located 28.25 kb
downstream of the gene origin and in the 29
th intron of the
MADD gene, was significantly associated with DHF for both
dominant models (OR 2.06 [95% CI 1.17–3.63, P=0.013])and
had a PAF of 12.02%. This SNP was located in a LD block (LD
block 2) spanning intron 27 to intron 32 of MADD gene
(Figure 1). The haplotypes within this LD block were
significantly associated with DHF. Among these haplotypes,
the haplotype C-C-G-C was associated with an increased risk
(OR 2.10 [95% CI 1.53–2.89], permuted P=0.029) of DHF
(Table 4). These findings suggest that there are strong
associations between LD block 2 and DHF.
Discussion
The present study shows an association between a specific SNP
and early DHF independent of hypertension. We used a pure
Han-Chinese population to eliminate false-positive results due to
population stratification. The current results demonstrated a novel
SNP that may predispose to development of DHF in the Han-
Chinese population.
The MYBPC3 gene encodes myosin-binding protein, a large
multidomain protein which comprises 11 modules, C0 to C10 (N
terminus to C terminus). The protein has been reported to play
important roles in both health and disease [21]. The MYBPC3
isoform contains protein kinase A phosphorylation sites within the
S2 binding site that are absent in skeletal muscle isoforms. Further,
recent data suggest that phosphorylated MYBPC3 may be
cardioprotective [22]. Variable disease phenotypes and prognoses
have been reported with different MYBPC3 gene mutations.
However, the findings from most studies suggest that MYBPC3
mutations are associated with late-onset, mild hypertrophy and
incomplete penetrance [23,24], as per DHF.
Recently, Dhandapany and colleagues reported that individuals
in a south Asian population who were heterozygous for a common
Figure 1. Graphical representation of SNPs in relation to the exon-intron structure (upper line) and Haploview LD graph of the
MYBPC3 gene and the adjacent SPI1 and MADD genes (lower panel). The exon regions are shown with filled rectangles and are numbered in
order. Pairwise LD coefficients D96100 are shown in each cell (D9 values of 1.0 are not shown). A standard Haploview color scheme was applied for
the LD color display (logarithm of odds [LOD] score $2 and D9=1, shown in bright red; LOD score $2 and D9,1 shown in pink; LOD score,2 and
D9=1 shown in blue; LOD score,2 and D9,1 shown in white).
doi:10.1371/journal.pone.0035242.g001
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onset, mild HCM [12]. We found that there was no such deletion
in a homogenous Han Chinese population. We systemically
screened the tagSNP from the upstream promoter to the
downstream neighboring gene. We studied a homogenous
Taiwanese population to eliminate false-positives due to popula-
tion stratification. Further, patients with CAD were excluded from
our study and the percentage of patients with hypertension was
nearly identical in both the DHF group and the control group.
Therefore, the confounding effects of CAD and hypertension (the
most common risk factors for DHF) were eliminated. In our
cohort, DHF was caused by diastolic dysfunction, or more
specifically, by abnormalities in active relaxation or passive
stiffness of the LV.
To elucidate the mechanism by which MYBPC3 causes disease
and structural changes, knockout mice, heterozygous (+/2) and
homozygous (2/2), were produced by deleting exons 3 through
10 on the endogenous cardiac MYBPC3 gene [14]. Studies have
revealed that MYBPC3 +/2 mice are indistinguishable from wild-
type control mice whereas MYBPC3 2/2 mice exhibit significant
cardiac hypertrophy. Removal of MYBPC3 can increase the
velocity of shortening and force output [25] and lower the amount
of phosphorylated MYBPC3 in the failing human heart [26]. We
suspect that a minor modification to the MYBPC3 gene, such as a
SNP or DNA phosphorylation, might contribute to the develop-
ment of HCM. Interestingly, the SNP rs2290149 identified in our
study to be associated with DHF was located in an LD block
containing the 39 untranslated region of the MYBPC3 gene and the
MADD gene. Whether this SNP plays a role in regulating MYBPC3
gene expression or is in LD with another functional polymorphism
of the MYBPC3 gene remains to be determined. Our findings
suggest that the MADD gene may also be associated with an
increased risk of DHF.
The MADD gene encodes MAPK-activating death domain-
containing protein. This protein can modulate the tumor necrosis
factor-alpha (TNF-a) activated NF-kappa beta, MAPK, ERK1/2,
JNK, and p38 pathway by interacting with TNFR1. In vitro
studies have demonstrated that MADD plays an essential in
counteracting the actions of TNF-a [27]. Tumor necrosis factor-
alpha has been found to induce time-dependent phosphorylation









value OR (95% CI) Allelic P Permuted P*
Case Control
1 rs3740689 26.41 SPI1gene
Intron 3
A/G 0.463 0.423 0.236 1.19 (0.88–1.60) 0.288 0.890
2 rs3824869 24.07 SPI1 gene
Intron 4
T/C 0.293 0.273 0.028 1.10 (0.79–1.53) 0.558 0.99
3 rs1057233 22.27 59 Upstream
promoter
C/T 0.259 0.304 0.023 0.80 (0.57–1.11) 0.180 0.759
4 rs2697920 3.56 Intron 5 A/G 0.463 0.480 0.616 0.93 (0.69–1.26) 0.651 0.99
5 rs2856650 8.97 Intron 11 T/C 0.276 0.324 0.446 0.79 (0.57–1.10) 0.162 0.724
6 rs10769253 11.83 Intron 19 G/A 0.426 0.412 0.858 1.06 (0.79–1.43) 0.702 0.99
7 rs2305280 23.88 MADD gene
Intron 32
C/T 0.398 0.372 0.435 1.11 (0.89–1.51) 0.486 0.989
9 rs753992 24.32 MADD gene
Intron 30
C/T 0.420 0.418 0.403 1.01 (0.75–1.36) 0.939 1.00
9 rs7124958 26.91 MADD gene
Intron 30
C/T 0.406 0.381 0.484 0.90 (0.66–1.22) 0.488 0.99
10 rs2290149 28.25 MADD gene
Intron 29
G/A 0.125 0.062 0.728 2.14 (1.25–3.66) 0.004 0.031
11 rs11039179 28.37 MADD gene
Intron 28
T/C 0.034 0.031 0.620 1.09 (0.48–2.51) 0.832 1.00
12 rs10838692 29.07 MADD gene
Intron 27
T/C 0.287 0.321 0.304 0.85 (0.62–1.18) 0.326 0.948
UTR, untranslated region; HW, Hardy-Weinberg; MAF, minor allele frequency.
*Permutation 10,000 times.
doi:10.1371/journal.pone.0035242.t003
Table 4. MYBPC3 and MADD gene haplotype/DHF association
analysis.
Haplotype Frequencies OR (95% CI) Nominal P Permuted P*
Case Control
Block 1
A-T 0.556 0.585 0.89 (0.74–1.06) 0.4466 1.000
G-C 0.380 0.369 1.05 (0.87–1.26) 0.7552 1.000
G-T 0.046 0.043 1.07 (0.70–1.64) 0.8556 1.000
A-C 0.017 0.003 5.75 (1.68–19.68) 0.063 0.2458
Block 2
T-T-A-C 0.577 0.582 0.98 (0.82–1.17) 0.8786 1.000
C-C-A-T 0.281 0.318 0.84 (0.69–1.02) 0.2849 0.8334
C-C-G-C 0.122 0.062 2.10 (1.53–2.89) 0.0063 0.0295
C-T-A-C 0.009 0.034 0.26 (0.12–0.54) 0.0188 0.0884
*Permutation 10,000 times.
doi:10.1371/journal.pone.0035242.t004
MYBPC3, MADD Gene and DHF
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35242of ERK, MSK1, and phospholamban on the threonine 17 residue
via TNFR1 [7]. Low concentrations of TNF-a (200 to 500 U/mL)
acutely decrease action potential duration, peak Ca
2+ transient
amplitude, and the rate of Ca
2+ decline [28]. In addition, TNF-a
can also mediate b-AR sensitivity by nitrous oxide-dependent
mechanisms, thus leading to diastolic dysfunction [29]. Further in
vitro and gene mapping studies are needed to determine whether
the SNPs in the MADD gene are associated with altered activation
of the aforementioned pathways warrants. The SNP rs2290149 is
located in a genetic cluster of MYBPC3 and MADD gene. The
haplotype that associated with DHF contained the regions of both
genes. Therefore, both of the above genes are possible targets to be
associated with DHF. Further fine mapping and functional studies
are warranted to prove whether MADD gene are associated with
DHF or that the SNP is involved in the regulation of MYBPC3
gene. Our current study could only provide evidence that tag SNP
rs2290149 is associated with the development of DHF.
Our study has several limitations that warrant mention. Of note,
our sample size was relatively small. However, we used an
individual risk-factor matched design to select control patients,
substantially increasing statistical efficiency and power and
decreasing the number of case-control pairs needed to obtain a
significant result. Further studies of other ethnic populations are
needed. According to our current definition, patients with
moderate and severe DHF were not included in this study and
the results should not be extrapolated to patients with moderate or
severe DHF.
In conclusion, we suggest that development of DHF may have a
genetic component. We identified the genetic variant SNP
rs2290149 to be associated with DHF and have a substantial
PAF in the Chinese population studied.
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